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Abstract: The idiopathic inflammatory myopathies are character-
ized by chronic muscle inflammation and involvement of internal
organs, which contribute considerably to the morbidity and mor-
tality of the disease. We conducted the current study to determine
the survival data for patients with idiopathic inflammatory myo-
pathies according to the presence of extramuscular clinical
manifestations. We also determined the cumulative survival prob-
ability and the long-term prognosis and analyzed the causes of death
at a single clinical immunology center.
A survival analysis was performed using data for 162 patients
diagnosed between 1976 and 1997 according to Bohan and Peter’s
criteria. Patients were followed up for a minimum of 5 years
(median, 101.5 mo) or to date of death. Cumulative survival prob-
ability was calculated by the Kaplan-Meier method. The influence
of extraskeletal and extramuscular involvement was analyzed as
prognostic factors for death by Cox proportional hazards survival
model.
Eighteen disease-specific deaths occurred; pulmonary and
cardiac complications were the most frequent causes of death.
Global survival rates were 95%, 92%, and 89% for 1, 5, and
10 years, respectively. Analysis for clinicopathologic subgroups
revealed that cancer-associated myositis had the worst prognosis,
while juvenile and overlap myositis had the best prognosis. Five-
and 10-year survival rates were 94.2% and 89.4% for patients with
primary polymyositis and 90.1% and 86.4% for primary dermato-
myositis patients, respectively. In the whole group of patients with
idiopathic inflammatory myopathy, cardiac (p < 0.01) and res-
piratory muscle involvement (p = 0.045) were significant prog-
nostic factors for death. In the group of patients with primary
polymyositis/dermatomyositis, cardiac involvement was the main
prognostic factor for death (p < 0.01).
Myositis patients described in this study have higher survival
rates than reported previously worldwide. We examine the reasons
for the differences between the data in the current study and the
available survival data in the relevant literature.
(Medicine 2004;83:35–42)
INTRODUCTION
T he idiopathic inflammatory myopathies (IIMs) aresystemic autoimmune diseases characterized by chronic
muscle inflammation resulting in progressive weakness and
frequent involvement of internal organs, mainly the pulmo-
nary, gastrointestinal, and cardiac systems, which contribute
considerably to the morbidity and mortality of the IIMs. Mor-
tality rate was 50% in a year for the most frequent
myopathies, polymyositis (PM) and dermatomyositis (DM),
before the widespread use of glucocorticoids1. In the past
decades, earlier diagnosis and adequate treatment regiments
have become the standard of care, so survival of patients
with IIMs has improved progressively worldwide10,18.
We report here a long-term study of 162 Hungarian
patients who were followed at a single clinical immunology
center with a particular interest in the disease and which is
responsible for the health provision of about 2.5 million
people. Our series represents most of the types of IIMs
defined by Bohan and Peter. To our knowledge, this is among
the largest survival studies on patients with IIMs in the world.
METHODS
Patient Selection: Recruitment and
Analysis Dates
We identified 162 consecutive inpatients and out-
patients who were diagnosed, treated, and followed by the
Abbreviations: DM = dermatomyositis, IIM = idiopathic inflammatory
myopathy, PM = polymyositis.
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3rd Department of Internal Medicine, University of Debre-
cen, Hungary. The diagnosis of IIM was made between 1
January 1976 and 31 December 1997. We analyzed the medical
records retrospectively and recorded the following data: age,
sex, time of diagnosis, duration of symptoms before the
diagnosis was made, extraskeletal and extramuscular manifes-
tations at any time during the clinical course, and date of death
or end of follow-up. All patients were white.
Diagnosis
Diagnosis of IIM was based on the criteria defined by
Bohan and Peter3 in all cases:
1. Progressive, symmetric weakness of proximal muscles;
2. Elevation of creatinine-kinase, lactate acid dehydrogenase;
3. Characteristic triad of electromyographic alterations;
4. Muscle biopsy evidence;
5. Characteristic dermatologic features in DM.
Patients were classified into clinicopathologic sub-
groups according to the Bohan and Peter schema as follows:
I. Primary, adult PM;
II. Primary, adult DM;
III. Juvenile idiopathic inflammatory myositis: below 18
years old at onset of disease, both DM and PM;
IV. Cancer-associated myositis;
V. Overlap myositis: myositis associated with all or some
clinical and immunologic features of another systemic
autoimmune disease (fulfill partly or completely the
diagnostic criteria of another connective tissue disease).
Clinical Evaluation
At the time of diagnosis all patients underwent a
standardized clinical evaluation to detect extramuscular
(Raynaud phenomenon, interstitial lung disease) and extra-
skeletal (dysphagia, cardiac and respiratory muscle involve-
ment) manifestations:
1. Chest radiograph, pulmonary function tests, high-
resolution computerized tomography (CT) scan of the
lungs;
2. Electrocardiogram, echocardiography, Holter monitoring;
3. Dysphagia—clinical history of disordered swallowing,
requirement for nasogastric tube;
4. Nailfold capillary microscopy.
During the clinical course of the disease, these tests
were usually repeated annually or as required (for example,
if a relapse occurred).
Systemic involvement was defined as follows:
1. Interstitial lung disease was considered if chest radio-
graph and/or high-resolution CT scan indicated the
presence of bibasilar interstitial fibrosis or alveolar
infiltrates; with pulmonary function tests abnormalities
characterized by a restrictive pattern.
2. Diagnosis of cardiac involvement was based on the ex-
clusion of other causes of rhythm disturbances, conduc-
tion defects, myocarditis, cardiomyopathy, and congestive
heart failure. In some cases (8 from the total of 15 patients
with cardiac involvement), a histopathologic evaluation
confirmed the presence of cardiac involvement.
3. Respiratory muscle involvement, resulting from the weak-
ness of the respiratory musculature, was considered if
patients had ventilatory failure with decreased vital-
capacity.
Diagnosis of extramuscular and extraskeletal manifes-
tations was considered if other causes of interstitial lung dis-
ease, dysphagia, cardiac involvement, or respiratory muscle
involvement were excluded.
Duration of Follow-Up and Endpoints
The data collection for this study was terminated by
1 December 2002, when the present study was performed.
Duration of follow-up was determined from time 0 cor-
responding to the date of diagnosis to either the date of death
or the date of the latest appearance at our department
(endpoints). The median follow-up was 101.5 months for
surviving patients (range, 5.0–312.5 mo; 25th percentile:
65.7 and 75th percentile: 144.1) and 47.5 month for patients
who died due to IIM (range, 0.03–234.5 mo; 25th percentile:
2.3 and 75th percentile: 107.3). In the group of patients with
primary PM/DM, median duration of follow-up was 96.0
months for surviving patients (range, 5.0–276.0 mo; 25th
percentile: 58.7 and 75th percentile: 144.1) and 59 months
for patients who died due to IIM (range, 0.03–145.0 mo;
25th percentile: 1.1 and 75th percentile: 96.0).
Of the 162 IIM patients, 119 patients were followed
for a minimum of 5 years (except for those who had died
earlier), and 32 patients (19.7%) were lost to follow-up.
Among 117 patients with primary PM/DM, 82 were followed
for a minimum of 5 years (except for those who had died
earlier), and 27 patients (23.1%) were lost to follow-up. Data
of these dropout patients were included in the calculation of
cumulative survival probability. All of the dropout patients
were in remission when we lost contact. We speculate that
most of these patients were lost due to a complete recovery
(24/32 patients had a monophasic disease). Therefore, the
survival probability may be underestimated.
The causes of death were evaluated by autopsy or
death certificate: when a patient died in our department or in
another hospital, we used the date and cause of death that
appeared in the autopsy record (14 patients). When the death
occurred outside the hospital, we used the cause of death
stated in the death certificate (6 patients).
Prognostic Factors
We selected clinical features characteristic of IIM in
addition to skeletal muscle weakness. The following
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prognostic factors were considered: gender, age at time of
diagnosis, presence of Raynaud phenomenon, interstitial
lung disease, dysphagia, respiratory muscle involvement and
cardiac involvement at any time in the clinical course. We
did not analyze the effect of myositis-specific autoantibodies
on survival because the tests for these autoantibodies were
not available in some patients at the time of diagnosis. There
were no missing values among the prognostic factors in the
data set.
Statistical Analysis
Data were analyzed using SPSS for Windows 10.0
statistics software. Differences in frequencies of systemic
manifestations among the clinicopathologic subgroups and
correlation among the supposed prognostic factors were
examined using the chi-square test. The survival curves were
drawn using the Kaplan-Meier method. The log-rank test was
used to determine the statistical significance of the observed
differences in survival rates between patient groups.
Stratified Cox regression analysis with forward stepwise
variable selection method was used to assess the variables
predicting death4. The number of events was insufficient to
analyze the interactions between the variables—this would
lead to instability in the Cox model, so we decided to discard
interactions. P values equal to or less than 0.05 were con-
sidered significant.
RESULTS
Clinical Characteristics
Clinical characteristics of our cohort of IIM patients
are presented in Table 1. Distribution of clinicopathologic
subgroups revealed that the most frequent forms were PM
(46.3%) and DM (25.9%). Age distribution exhibited the
classical bimodal pattern with peaks at 10–15 and 35–45
years of age. The mean age at the time of diagnosis was
different among the subgroups: PM and overlap myositis
patients were younger at the onset of the disease than DM
and cancer-associated myositis patients. The female:male
ratios were also different among the subgroups: there were
larger female:male ratios in DM and overlap myositis
patients than in PM patients. However, males were more
predominant than females in the groups of juvenile patients
and cancer-associated myositis. All cancer-associated myo-
sitis patients had DM.
Further analysis of patients with primary PM/DM
revealed that most of the PM patients had definite myositis
(58 patients), while 17 had probable PM. The median
duration of symptoms preceding the diagnosis was 5 months
(range, 0.25–120 mo). Among patients with DM, 40 patients
were considered to have definite DM and 2 had probable
DM. The median onset of muscular and/or cutaneous
symptoms was 2 months (range, 0.25–24 mo) before the
diagnosis of DM. Proximal muscle weakness was present in
all patients; and in the cases of DM, all the patients showed
the typical skin manifestations. Frequencies of extraskeletal
and extramuscular manifestations present at any time in the
clinical course are shown in Table 2. Dysphagia was sig-
nificantly more frequent among DM patients (p = 0.0372),
while other systemic manifestations (cardiac and respiratory
muscle involvement, interstitial lung disease, Raynaud phe-
nomenon) were observed to a similar extent among PM and
DM patients.
Causes of Death
Twenty patients died in our cohort of patients.
Eighteen disease-specific deaths occurred at a mean age of
49.3 ± 10.1 years (range, 30–65 yr), after a median duration
follow-up of 30 months (range, 0.03–234.5 mo). The global
survival curve of our patients (Figure 1) shows that the
mortality of myositis is higher during the first year after
diagnosis than later in the course. Of those patients with
disease-related death, 8 died within 12 months after the
diagnosis and 7 patients died more than 5 years after the
diagnosis of myositis. The female:male ratio of the deceased
(9 female:9 male patients) was not similar to the ratio typical
of the disease. Causes of death were cardiac (11 patients),
pulmonary (4 patients), and gastrointestinal (1 patient) com-
plications and cancer (in 2 patients who had cancer-
associated myositis). Pulmonary complications occurred
mostly within the first 12 months, while cardiovascular
complications caused death mainly after 5 years’ disease
duration. In the groups of primary PM/DM, 13 disease-
specific deaths were observed: 4 deaths were due to
pulmonary complications (1 PM patient had severe oropha-
ryngeal dysfunction leading to aspiration pneumonia and 3
DM patients had respiratory muscle involvement resulting in
pulmonary insufficiency), 8 deaths were due to cardiovas-
cular manifestations (2 cases of arrhythmia, 3 of heart
failure, 2 of cardiac arrest, and 1 case of myocardial
TABLE 1. Characteristics of Patients with Idiopathic
Inflammatory Myopathies: By Clinicopathologic Subgroup
No. of
Patients (%)
Female:
Male
Ratio
Age at
Time of
Diagnosis (yr)
All Patients 162 (100) 2.1:1 39.2 ± 13.6
Polymyositis 75 (46.3) 1.8:1 39.3 ± 11.1
Dermatomyositis 42 (26.0) 2.8:1 43.7 ± 12.4
Juvenile patients 9 (5.5) 1:2 10.4 ± 4.4
Cancer/associated
myositis
7 (4.3) 1:1.3 48.6 ± 18.7
Overlap myositis 29 (17.9) 4.8:1 39.4 ± 10.9
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infarction) and 1 death was due to gastrointestinal compli-
cations (1 PM patient who had toxic megacolon).
Difference Among Clinicopathologic Subgroups
Global survival rates were 95%, 92%, and 89% for 1,
5, and 10 years, respectively. Survival analysis for further
clinicopathologic subgroups (see Figure 1) revealed that
patients with various forms of IIMs have different survival
rates. None of the juvenile patients in our study died. Cancer-
associated myositis patients had a survival curve signifi-
cantly different from the other subgroups (p = 0.03). Further,
although overlap myositis patients had the best prognosis,
there was actually no significant difference from the other
subgroups (p = 0.65). All 3 deaths in the overlap myositis
subgroup were due to cardiovascular complications, and both
of the 2 deaths in the cancer-associated myositis subgroup
were the consequence of the underlying malignant disease.
Five- and 10-year survival rates were 94.2% and
89.4% for patients with primary PM and 90.1% and 86.4%
for patients with primary DM. There was no significant
difference between PM and DM survival curves (p = 0.5417).
Both the 5- and 10-year survival rates were 96% for overlap
myositis patients and 71% for patients with cancer-associated
myositis, respectively.
Influence of Clinical Features on Survival
The effects of different extraskeletal and extramuscular
manifestations were evaluated in the group of patients with
primary PM/DM (Figures 2 and 3). PM patients with
dysphagia (p < 0.01) and cardiac involvement (p < 0.01)
had significantly worse cumulative survival probability than
PM patients without dysphagia or cardiac involvement. In
the group of patients with DM, survival was significantly
worse for male patients (p = 0.0382), patients who were older
than 45 years at time of diagnosis (p = 0.0217), patients with
interstitial lung disease (p = 0.0228), and patients with
cardiac involvement (p < 0.01).
FIGURE 1. Survival curves of patients with idiopathic inflammatory myopathies (left) and survival curves according to
clinicopathologic subgroups (right). JDM indicates juvenile dermatomyositis; OM, overlap myositis; PM, polymyositis;
DM, dermatomyositis; CAM, cancer-associated myositis.
TABLE 2. Frequency of Extraskeletal and Extramuscular Manifestations in Patients with Idiopathic Inflammatory Myopathies
IIM (n = 162) PM (n = 75) P DM (n = 42) P
No. (%) No. (%) No. (%)
ILD 36 (22.2) 16 (21.3) NS 11 (26.2) NS
Dysphagia 31 (19.1) 7 (9.3) NS 15 (35.7) 0.0372
Respiratory muscle involvement 26 (16.0) 12 (16.0) NS 9 (21.4) NS
Cardiac involvement 15 (9.3) 7 (9.3) NS 2 (4.7) NS
Raynaud phenomenon 51 (31.5) 25 (33.3) NS 11 (26.2) NS
Abbreviations: IIM = idiopathic inflammatory myopathies; PM = polymyositis; DM = dermatomyositis; NS = not significant; ILD = interstitial lung disease.
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Prognostic Factors
Although the chi-square test of variables revealed a cor-
relation between cardiac and respiratory muscle involvement,
we analyzed the effect on survival of the presence of different
clinical manifestations in a multivariate model, too. Significant
prognostic factors for death determined in the whole group of
patients with IIM were cardiac (coefficient = 3.182; p < 0.01)
and respiratory muscle involvement (coefficient = 1.16;
p = 0.045). In the group of patients with primary PM/DM,
cardiac involvement was the main prognostic factor for death
(coefficient = 3.553; p < 0.01).
DISCUSSION
We report a long-term survival study on patients with
myositis who were diagnosed, treated, and followed in a
single clinical immunology department in Hungary. Our
cohort of IIM patients represents most of the clinicopatho-
logic forms, and their clinical characteristics (distribution of
different types, female:male ratio, age distribution, and
frequencies of extraskeletal and extramuscular involvement)
were similar to those in other series in the literature10,12,17.
Available data on survival of patients with IIMs, based
on studies with sufficient numbers of patients, come from the
United States, England, France, and Israel (Table 3). The
clinicopathologic subgroups of IIMs included in these
studies differ considerably. Therefore, to compare our work
with data of the relevant literature, we decided to report the
survival probability for the whole group of IIM patients as
well as for primary PM/DM patients in our series. However,
survival studies are influenced by several factors that modify
FIGURE 2. Survival curves of patients with primary polymyositis with or without interstitial lung disease (top left) and respiratory
muscle involvement (bottom left); and patients with dermatomyositis with or without interstitial lung disease (top right) and
respiratory muscle involvement (bottom right). PM indicates polymyositis; DM, dermatomyositis; ILD, interstitial lung disease;
NS, not significant.
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the results considerably, and the observed differences in
mortality rates are attributable to 1) the means of selection of
patients (diagnostic criteria, recruitment from a single or
more than 1 department, which subgroups of IIMs are
included in the analysis); 2) involving a sufficient number of
patients and inclusion or exclusion of data of cases lost to
follow-up; and 3) the duration of follow-up.
Myositis patients in the current study had higher
survival rates than previously reported worldwide. This may
be attributable to 3 aspects, discussed below: 1) these large
series were based on patients who were diagnosed 2–3
decades before2,8,14; 2) the distribution of clinicopathologic
subgroups was not similar, especially the frequency of
cancer-associated cases; and 3) improved diagnostic tools
and therapeutic modalities have resulted in an increase in
survival rates.
First, comparison of survival data is limited by the fact
that studies reported by Medsger et al14 and Hochberg et al8
had started before Bohan and Peter published their diagnostic
criteria in 19753.
Second, all of these long-term large series had different
inclusion criteria, especially concerning the subgroups of
IIMs they studied. The worst survival rates and prognosis
were experienced in studies that involved higher rates of
cancer-associated myositis patients2,13. Results of recent
long-term studies of IIM patients from France and England,
FIGURE 3. Survival curves of patients with primary polymyositis with or without dysphagia (top left) and cardiac involvement
(bottom left) and patients with dermatomyositis with or without dysphagia (top right) and cardiac involvement (bottom right).
PM indicates polymyositis; DM, dermatomyositis; NS, not significant.
40 n 2004 Lippincott Williams & Wilkins
Danko´ et al Medicine  Volume 83, Number 1, January 2004
which are more comparable to our experience, vary
considerably depending on whether cancer-associated myo-
sitis patients are excluded or not: Sultan et al18 reported a
95% 5-year survival rate, while Marie et al12 reported 77%.
Having different etiologic, clinical, and serologic features
from the other clinicopathologic forms of IIM, cancer-
associated myositis patients should not be included when
measuring the cumulative survival probability and prognosis
of IIM. Cancer-associated myositis patients having the worst
prognosis are hardly comparable with patients with other
forms of IIM, because prognosis and life expectancy is
determined by the underlying malignant disease. Consider-
ing that mainly DM patients have a higher risk for ma-
lignancy6, studies including cancer-associated cases among
DM patients report worse survival rates for patients with DM
than for those with PM.
Finally, improved survival of patients with IIM, and
other patients as well, can be attributed to the following:
1. Widespread use of new diagnostic tools and serologic
testing, which contribute to early diagnosis and to rec-
ognition of milder forms of the disease;
2. Early use of more appropriate and more aggressive
immunosuppressive and supportive therapy1;
3. Regular follow-up in departments specializing in the
disease;
4. Better general medical care;
5. Better understanding of the natural history of the disease.
Our survival curve was heterogeneous, with an accel-
erated mortality during the first year after diagnosis and a
slower mortality during the following 10 years, except for
those who had cardiac complications later in the clinical
course. We found no significant difference between groups
for patients with primary PM and primary DM, although most
of the studies report better survival rates for PM patients.
Major causes of death in the current study were similar to
the findings of the relevant literature9,18. Deaths due to
pulmonary complications were observed early in the course
(median, 1 mo) in our cohort of patients, and cardiovascular
complications occurred late in the course (median, 59 mo).
Myositis patients may have severe extraskeletal and
extramuscular manifestations—pulmonary, gastrointestinal,
and cardiac involvement—which often affect the prognosis
unfavorably. In patients with primary PM, the presence of
dysphagia and the presence of cardiac involvement were
associated with a significantly worse survival probability. In
patients with primary DM, survival rates were worsened
significantly by male gender, older age at the time of
diagnosis (more than 45 yr), presence of interstitial lung
disease, and presence of cardiac involvement. Effect of
pulmonary involvement, especially interstitial lung disease,
on survival may be controversial5,7,15, however, most
authors found higher mortality rates compared to patients
without interstitial lung disease 2,11.
Classic factors of poor prognosis are older age, male
sex, African-American race, interstitial lung disease, pres-
ence of anti-Jo-1 and anti-SRP autoantibodies, associated
malignancy, delayed or inadequate treatment, dysphagia,
dysphonia, cardiac involvement, and pulmonary involve-
ment 2,9,10,13. In our study, unfavorable prognostic signs were
respiratory muscle and cardiac involvement.
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